Title: LegoChem
Biosciences receives patent for a novel oxazolidinone derivative… Publication: Disclosed
on Kosdaq Date: 19 August 2014 URL: link to website (contents
in Korean)
Summary
LegoChem Biosciences received a
patent in U.S. on Aug. 14, for a novel oxazolidinone derivative and medical
composition containing same. (Application No.14/008,702) About LegoChem Biosciences
LegoChem Biosciences, Inc. (LCB) is a
research-based biotechnology company dedicated to discovering, developing, and
commercializing innovative medicines by leveraging our chemistry expertise to
make conventional biologics targeted and more potent for the benefit of
patients with diseases of high unmet medical needs. We are advancing
sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants,
oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). |
|
IP : 106.243.208.*** 
|
